

Science Editor
World Journal of Clinical Cases
Fang-Fang Ji

Mar 29, 2017

Dear Dr. Fang-Fang Ji,

Thank you and the reviewers for a thorough review of our manuscript entitled “**Effect of double platinum agents, including miriplatin and cisplatin, in patients with hepatocellular carcinoma: Report of two cases**” (Manuscript number 32580, **INVITED REVIEW ID 00188507**) by Kohei Ogawa, Yukari Watanabe, Yosuke Motai, Daisuke Kumaki, Ryoya Seki, Akira Sakamaki, Satoshi Abe, Hirokazu Kawai, Tkaeshi Suda, Satoshi Yamagiwa, Shuji Terai, and myself. The thoughtful comments from the reviewers are greatly appreciated. In preparing for revision, we have carefully studied reviewers’ comments and incorporated many of their suggestions into the revised manuscript. For your convenience, we have highlighted the changes made in blue. We hope this revised manuscript is now acceptable for publication in *World Journal of Clinical Cases*. **The provided ID for this invited review is (00188507).**

We declare that this work is original, the manuscript is not under consideration by other journals, and the material has not been previously published. All authors approved the contents submitted. We look forward to hearing from you at your earliest convenience.

Thank you for your consideration.
Sincerely yours,

Kenya Kamimura, M.D., Ph.D.
Division of Gastroenterology and Hepatology
Graduate School of Medical and Dental Sciences
Niigata University
1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 9518510, JAPAN
Tel: +81 (25) 227-2207
Fax: +81 (25) 227-0776
E-mail: kenya-k@med.niigata-u.ac.jp

Dear Reviewers:

Thank you very much for your thoughtful comments and suggestions. In preparing the revision, we have carefully studied your comments and incorporated many of your suggestions into the revised manuscript. The following are our point-by-point responses to your comments/concerns. For your convenience, we have highlighted the changes made in blue.

Title: Effect of double platinum agents, including miriplatin and cisplatin, in patients with hepatocellular carcinoma: Report of two cases
(Author ID 00188507)

Author: Kohei Ogawa, Kenya Kamimura, Yukari Watanabe, Yosuke Motai, Daisuke Kumaki, Ryoya Seki, Akira Sakamaki, Satoshi Abe, Hirokazu Kawai, Tkaeshi Suda, Satoshi Yamagiwa, Shuji Terai

Name of Journal: *World Journal of Clinical Cases*

ESPS Manuscript NO: 32580

Reviewer #1

well done paper, it can be published after minor revision:

Response: We appreciate for a thorough review of our manuscript and are grateful for the positive comments.

1. *Please detail better: - how you infuse the drug - how many minutes the infusion lasts - dosage and dilution of drug infused - type of periprocedural medication adopted*

Response: We have added the description (page 6, line 2 from the bottom; page 8, line 8 from the bottom).

2. *on page 8 better specify which kind of RFA you use*

Response: We have added the information in page 9, line 3.

3. *One last comment is on the references: please reduce the number of references, eliminating the oldest*

Response: We have deleted the oldest reference.

Reviewer #2

Title: The title should specify the employed technique more exactly.

Response: We are grateful to the reviewer for the positive comments and for recognizing the significance of our work. We have modified the title to specify the technique.

1. *"Core Tip": The term "completer response" should not be used.*

Response: Thank you for your thorough review on our manuscript. We have modified the core-tip.

2. *Case Presentation 1, second paragraph: "Kupffer's phase"; Figure Legends: "Kupffer phase" -> please be consistent (I would suggest "Kupffer phase").*

Response: Thank you for your through review. We have changed to "Kupffer phase" according to your suggestion (page 6, line 11; page 7, line 6 from the bottom).

3. *Technique: Please provide a more detailed description of the procedure.*

Response: We agree with the reviewer's comment. We have added the description in page 6, line 2 from the

bottom and page 8, line 8 from the bottom.

4. "Author Contributions": The contribution of each author should be specified more clearly.

Response: Thank you for your thorough review on our manuscript. We have specified the contributions.

Reviewer #3

These cases appear to have responded which may be an important finding. Please comment on how these cases were selected for this study.

Response: We are grateful to the reviewer for the positive comments and for recognizing the significance of our work. We have added the description regarding the selection of cases in page 5, line 10 and page 6, line 4 from the bottom.

1. How many other cases did not respond? The follow up of these cases is relatively short. Can you comment on this.

Response: We appreciate the reviewer's comments. For other cases (approximately 20 cases) data are currently under the careful follow up and we are analyzing the therapeutic responses as a part of Phase II trial described in page 5, line 9. As they are showing the good therapeutic effect, therefore, we have chosen these 2 cases to show the efficacy to contribute on the development of novel HCC therapeutic option. Thank you again for your thoughtful comment, we really appreciated it.